Roflumilast placebo

DRUG4 trials

Sponsors

AstraZeneca, University of Miami

Conditions

Alzheimer's DiseaseAsthmaCOPDChronic Obstructive Pulmonary Disease (COPD)Memory Impairment

Phase 1

Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults

CompletedNCT02051335

AstraZenecaAlzheimer's Disease, Memory Impairment

Start: 2014-01-31End: 2014-05-31Updated: 2017-02-01

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

CompletedNCT02097992

University of MiamiCOPD

Start: 2013-02-28End: 2015-07-31Updated: 2017-11-24

Phase 2

Roflumilast Plus Montelukast in Adults With Severe Asthma

CompletedNCT01765192

AstraZenecaAsthma

Start: 2013-02-28End: 2013-10-31Updated: 2017-02-01

Phase 3

Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

CompletedNCT02165826

AstraZenecaChronic Obstructive Pulmonary Disease (COPD)

Start: 2014-05-01End: 2015-09-01Updated: 2017-04-20

Related Papers

Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.

2018-08-017 citations

pharmacokinetics and pharmacodynamics of a 4-week up-titration regimen of roflumilast in the optimize study

Pneumologie2018-02-211 citations

Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE)

2016-09-011 citations